Business Context and Reporting Period
Company: Alterity Therapeutics Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2021 (Specifically dated January 07, 2021)
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance update rather than financial performance.
Material Changes
- Executive Appointment: Dr. David Stamler has been appointed as Chief Executive Officer (CEO).
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on strategy, risks, contingencies, or unusual items beyond the announcement of the CEO appointment.
Investor Verification Checklist
- Verify the effective date of Dr. David Stamler's appointment as CEO.
- Confirm the background and prior experience of the new CEO.
- Check for any concurrent changes to the Board of Directors or Executive Chairman role (Geoffrey Kempler signed as Executive Chairman).
- Review subsequent filings for the impact of this leadership change on the company's strategic direction.